NASDAQ:AUPH
Aurinia Pharmaceuticals Inc Stock Company Profile
$5.03
-0.0600 (-1.18%)
At Close: Apr 24, 2024
Information
4464 Markham Street, Suite 1203
Victoria BC V8Z 7X8
250-708-4272
www.auriniapharma.com
Industry: Biotechnology
Sector: Healthcare
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
